Company intelligence / Profile preview
Nido Biosciences
Watertown, Massachusetts, United Statesnidobio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead candidate NIDO-361 has completed enrollment for a Phase 2 study with 54 patients in the EU, UK, and South Korea. The study will assess changes from baseline in total and thigh lean muscle volume (measured by MRI) as the primary endpoint.
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Nido Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nido Biosciences.